James Xu is an associate in in Goodwin’s Technology Companies & Life Sciences Group. Mr. Xu counsels clients in the high-tech and life sciences industries in public and private financing transactions, including initial public offerings, securities law reporting and compliance, mergers and acquisitions, governance and other general corporate matters. He joined Goodwin in 2010.




  • BioAmber in its $38.6 million and $35.1 million follow on public offerings
  • BMO Capital Markets, Stifel and the underwriting syndicate in Tokai Pharmaceuticals’s $97 million initial public offering
  • Borderfree in its $80 million initial public offering and subsequent $395 million sale to Pitney Bowes
  • Cowen and Company, Stifel and the underwriting syndicate in Nivalis Therapeutics’s $88 million initial public offering
  • Deutsche Bank, BofA Merrill Lynch, William Blair and the underwriting syndicate in Paylocity’s $138 million initial public offering
  • Esperion Therapeutics in its  $97 million and $201 million  follow-on public offerings
  • Leerink Partners, Credit Suisse and the underwriting syndicate in Edge Therapeutics’s $92 million initial public offering
  • Mimecast Limited in its $77.5 million initial public offering
  • Piper Jaffray, Stifel and the underwriting syndicate in Innocoll AG’s $59 million initial public offering, and Piper Jaffray in Innocoll AG’s $30 million follow-on public offering
  • ProQR Therapeutics in its $97.5 million initial public offering and its subsequent at-the-market public offering
  • Rapid Micro Biosystems in its $32 million Series B financing and subsequent  $25 million Series C financing
  • Vascular Biogenics Ltd. in its $40 million initial public offering and its subsequent $15 million follow-on offering
  • Virtusa in its $91 million follow-on public offering
Professional Experience

Prior to joining Goodwin, Mr. Xu was a Litigation Fellow at the Lawyers’ Committee for Civil Rights Under Law of the Boston Bar Association, practicing civil rights litigation in the areas of employment, housing and racial violence.

Mr. Xu co-authored “Consistency of Confusion? A Fifteen-Year Revisiting of Barton Beebe’s Empirical Analysis of Multifactor Tests for Trademark Infringement,” which was published in the Stanford Technology Law Review (2010 Stan. Tech. L. Rev. 3).

In The News







J.D., 2009
Harvard Law School
B.A., 2006
University of California, Davis



Get In Touch
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers